沃生物制药

最新新闻

• 公司公告
  Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/4/22
• 评级变动
  TD Cowen Maintains Vor Biopharma(VOR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 公司公告
  Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-10% Owner RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/10/6
• Wedbush Maintains Vor Biopharma(VOR.US) With Hold Rating, Raises Target Price to $27
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  A Quick Look at Today's Ratings for Vor Biopharma(VOR.US), With a Forecast Between $15 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/3/31
• 评级变动
  Wells Fargo Initiates Vor Biopharma(VOR.US) With Buy Rating, Announces Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/3/19
• Stifel Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Jefferies Initiates Vor Biopharma(VOR.US) With Buy Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/3/30
• Jefferies Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $48
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 公司公告
  Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/6/13
• 评级变动
  HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $31 Price Target
  Benzinga · 2026/5/19
• 公司公告
  Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/4/25
• 公司公告
  Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-10% Owner RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/7/22
• 评级变动
  Citi Initiates Vor Biopharma(VOR.US) With Buy Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/1/9
• Citi Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
  Dow Jones · 2026/5/19
• 评级变动
  H.C. Wainwright Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  H.C. Wainwright Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $31
  \u5e02\u573a\u8d44\u8baf · 2026/4/15
• 评级变动
  Wedbush Maintains Vor Biopharma(VOR.US) With Hold Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/5/14

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。